Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesThe hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosisA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesDNA vaccines against human immunodeficiency virus type 1.Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesLlama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesProtection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsInduction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccinesBiochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsComparing antigenicity and immunogenicity of engineered gp120.Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccinationCrosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesStabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesControl of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesNeutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression systemNoncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination.Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloStabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticA native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationGag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding siteCharacterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicityInclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
P2860
Q24561905-73F928CC-3267-4EBB-920F-303DD0F4D27CQ28263058-537821C7-1D57-4298-93AD-9FDB2AD7D94FQ28299280-A464F046-9446-4E69-B4FD-35DBBA824A79Q29307502-C9682C2A-4473-4F10-9AFC-F2C344389DB7Q29619015-35D10070-CEDA-4941-9677-29AF1713B909Q30342130-1171684A-6DDF-4E87-8CE8-41AA816766BCQ30360326-29D329F7-C95F-422E-A4B1-491C6E9AE32AQ30374995-E68796DB-692E-4648-A554-356A4E242C8FQ30379200-91638E71-2EA7-4053-A10D-158361982B98Q33274285-2EDA2F80-A43A-42F0-B6E7-9BD770FD7145Q33374701-54F4FB44-2298-4961-A118-1F5C3E1EEF96Q33648910-11CCCB5A-F176-48B5-88B8-3586B8D6A908Q33737723-C4941440-ADF9-4660-8153-7592C459927DQ33916676-7412D05A-428E-4A96-A4A3-78192C436053Q33930424-2E10B5D9-675C-4CE8-9BAB-8F905DE226ABQ33960361-3E129582-D7C8-45E7-AB29-2DE0BD02EA63Q33984309-9172B1F0-0D68-456C-9580-DBC681B288E2Q34074750-E6CA86D8-F284-4ABC-9947-93E92E45CF5FQ34154514-66D5A434-F0A6-40A6-A82D-F5EC7F06663EQ34299053-E8F001D6-629A-47F1-BD2A-DC97651884D2Q34302085-627FCDA1-9978-4666-96FE-567B2FD505B1Q34332284-55D1D109-B1DB-4682-B297-07220751C497Q34332728-71182523-F689-4158-9BBD-7C4D19880168Q34391256-E439E31C-A187-45F0-A9C7-9912F61EEC6EQ34462167-45412E28-F510-4B2B-9A16-E950AE21F1DCQ34465510-5974AB13-764E-432C-ABE8-2882AACECFB3Q34637968-79360576-04FB-4B71-9334-15A8A6473F12Q34754733-3BB85EE1-3607-4126-8C6C-5ED65E9070EBQ34785725-A71757A5-1DD4-4A32-9E48-DFEC8F95C5BCQ34976881-78B62A51-B3CB-43AA-B81E-100CB5041DF6Q35024202-49B92334-4FE4-4950-94F0-061F1AF26DB1Q35065249-20B1D4D1-A9B0-4EAE-B862-EC5E5DA515C1Q35110976-67FF5FAC-9510-45CE-8454-E6BA7CF3DB65Q35168642-984FA2FB-844A-4419-94C1-1F78E41574D4Q35487441-127EC651-55A7-4EBB-8572-3440C25191A9Q35548279-1A80E1EE-9365-41CC-8205-0447AA93362BQ35641498-7AE41515-A4D4-4C35-9817-72D68D73132DQ35774051-E60032FB-628C-4CBB-A0FA-B7BAF7DF8EC4Q35857631-9530E1F5-3EFF-440B-9C5D-D38D3B7884A3Q35883032-851EE334-6218-41E2-9A6B-1928A120F9C1
P2860
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@ast
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@en
type
label
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@ast
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@en
prefLabel
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@ast
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@en
P2093
P2860
P1433
P1476
Immunogenicity and protective ...... deficiency virus type 1 gp140.
@en
P2093
C C Broder
P2860
P304
P356
10.1128/JVI.75.2.645-653.2001
P577
2001-01-01T00:00:00Z